Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): Favorable activity of targeting EGFR- ErbB2 signaling with lapatinib

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 497-512

  Singh, Anjali ^a   Lun, Xueqing ^a   Jayanthan, Aarthi ^a   Obaid, Halah ^a   Ruan, Yibing ^a   Strother, Douglas ^b   Chi, Susan N ^a,c   Smith, Amy ^a,d   Forsyth, Peter ^e   Narendran, Aru ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Lapatinib; Targeted therapeutics; Teratoid Rhabdoid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BARASERTIB; CARFILZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; INK 128; LAPATINIB; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; POLO LIKE KINASE; PROTEASOME; SEPANTRONIUM BROMIDE; TIVOZANIB; UNCLASSIFIED DRUG; VOLASERTIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CELL MIGRATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; TERATOMA; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84878115093     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.01.001     Document Type: Article

References (51)

1. Abraham J., Prajapati S.I., Nishijo K., Schaffer B.S., Taniguchi E., Kilcoyne A., McCleish A.T., Nelon L.D., Giles F.G., Efstratiadis A., LeGallo R.D., Nowak B.M., Rubin B.P., Malempati S., Keller C. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics 2011 Apr, 10(4):697-707. Epub 2011 Mar 29.
2. Andreoli F., Barbosa A.J., Parenti M.D., Del Rio A. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Current Pharmaceutical Design 2012 Sep 26, [Epub ahead of print].
3. Arcaro A., Doepfner K.T., Boller D., Guerreiro A.S., Shalaby T., Jackson S.P., Schoenwaelder S.M., Delattre O., Grotzer M.A., Fischer B. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. The Biochemical Journal 2007, 406:57-66.
4. Bai X., Yan Y., Coleman M., Wu G., Rabinovich B., Seidensticker M., Alt E. Tracking long-term survival of intramyocardially delivered human adipose tissue-derived stem cells using bioluminescence imaging. Molecular Imaging and Biology: MIB: The Official Publication of the Academy of Molecular Imaging 2011, 13:633-645.
5. Beschorner R., Mittelbronn M., Koerbel A., Ernemann U., Thal D.R., Scheel-Walter H.G., Meyermann R., Tatagiba M. Atypical teratoid-rhabdoid tumor spreading along the trigeminal nerve. Pediatric Neurosurgery 2006, 42:258-263.
6. Bikowska B., Grajkowska W., Jozwiak J. Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2011, 18:813-818.
7. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer Journal 2010, 16:23-32.
8. Chattopadhyay A., Vecchi M., Ji Qs, Mernaugh R., Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor. Journal of Biological Chemistry 1999 Sep 10, 274(37):26091-26097.
9. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research 2010, 70:440-446.
10. Cruickshanks N., Hamed H., Bareford M.D., Poklepovic A., Fisher P.B., Grant S., Dent P. Lapatinib and Obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology 2012.
11. D'Cunja J., Shalaby T., Rivera P., von Buren A., Patti R., Heppner F.L., Arcaro A., Rorke-Adams L.B., Phillips P.C., Grotzer M.A. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. European Journal of Cancer 2007, 43:1581-1589.
12. de Souza J.A., Davis D.W., Zhang Y., Khattri A., Seiwert T.Y., Aktolga S., Wong S., Kozloff M.F., Nattam S., Lingen M.W., Kunnavakkam R., Stenson K.M., Blair E.A., Bozeman J., Dancey J.E., Vokes E.E., Cohen E.E. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clinical Cancer Research 2012.
13. Dimitropoulos K., Giannopoulou E., Argyriou A.A., Zolota V., Petsas T., Tsiata E., Kalofonos H.P. The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. Anticancer Research 2010, 30:4987-4992.
14. Dolloff N.G., Mayes P.A., Hart L.S., Dicker D.T., Humphreys R., El-Deiry W.S. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Science Translational Medicine 2011, 3:86ra56.
15. Eccles S.A. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. The International Journal of Developmental Biology 2011, 55:685-696.
16. Foster K., Wang Y., Zhou D., Wright C. Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival. Cancer Chemotherapy and Pharmacology 2009, 63:783-791.
17. Foster K.S., McCrary W.J., Ross J.S., Wright C.F. Members of the hSWI/SNF chromatin remodeling complex associate with and are phosphorylated by protein kinase B/Akt. Oncogene 2006, 25:4605-4612.
18. Freudenberg J.A., Wang Q., Katsumata M., Drebin J., Nagatomo I., Greene M.I. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Experimental and Molecular Pathology 2009, 87:1-11.
19. Fujisawa H., Misaki K., Takabatake Y., Hasegawa M., Yamashita J. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation. Journal of Neuro-Oncology 2005, 73:117-124.
20. Gorlick R., Kolb E.A., Houghton P.J., Morton C.L., Phelps D., Schaiquevich P., Stewart C., Keir S.T., Lock R., Carol H., Reynolds C.P., Maris J.M., Wu J., Smith M.A. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer 2009, 53:594-598.
21. Guidi C.J., Sands A.T., Zambrowicz B.P., Turner T.K., Demers D.A., Webster W., Smith T.W., Imbalzano A.N., Jones S.N. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Molecular and Cellular Biology 2001 May, 21(10):3598-3603.
22. Hasselblatt M., Isken S., Linge A., Eikmeier K., Jeibmann A., Oyen F., Nagel I., Richter J., Bartelheim K., Kordes U., Schneppenheim R., Frühwald M., Siebert R., Paulus W. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 2012 Oct 17, [Epub ahead of print]. 10.1002/gcc.22018.
23. Hegde P.S., Rusnak D., Bertiaux M., Alligood K., Strum J., Gagnon R., Gilmer T.M. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Molecular Cancer Therapeutics 2007, 6:1629-1640.
24. Jayanthan A., Bernoux D., Bose P., Riabowol K., Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: evidence for synergy with Topoisomerase-I inhibition. Cancer Cell International 2011, 11:44.
25. Jin Q., Esteva F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2008 Dec, 13(4):485-498.
26. Kieran M.W., Roberts C.W., Chi S.N., Ligon K.L., Rich B.E., Macconaill L.E., Garraway L.A., Biegel J.A. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood and Cancer 2012 Dec 15, 59(7):1155-1157.
27. Knipstein J.A., Birks D.K., Donson A.M., Alimova I., Foreman N.K., Vibhakar R. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro-Oncology 2012, 14:175-183.
28. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., Keith B.R., Gilmer T.M., Berger M., Podratz K.C., Slamon D.J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Research 2006, 66:1630-1639.
29. LaBonte M.J., Wilson P.M., Fazzone W., Russell J., Louie S.G., El-Khoueiry A., Lenz H.J., Ladner R.D. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Research 2011 May 15, 71(10):3635-3648.
30. Liang C.C., Park A.Y., Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2007, 2:329-333.
31. Lun X., Alain T., Zemp F.J., Zhou H., Rahman M.M., Hamilton M.G., McFadden G., Bell J., Senger D.L., Forsyth P.A. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Research 2010, 70:598-608.
32. Mukohara T. Role of HER2-targeted agents in adjuvant treatment for breast cancer. Chemotherapy Research and Practice 2011, 2011:730360.
33. Nabzdyk C.S., Chun M., Pradhan L., Logerfo F.W. High throughput RNAi assay optimization using adherent cell cytometry. Journal of Translational Medicine 2011, 9:48.
34. Nahta R., Yuan L.X., Du Y., Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Molecular Cancer Therapeutics 2007, 6:667-674.
35. Narendran A., Coppes L., Jayanthan A., Coppes M., Teja B., Bernoux D., George D., Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. Journal of Neuro-Oncology 2008, 90:171-180.
36. O'Donovan N., Byrne A.T., O'Connor A.E., McGee S., Gallagher W.M., Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investigational New Drugs 2011, 29:752-759.
37. Ogino S., Cohen M.L., Abdul-Karim F.W. Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 1999, 12:379-385.
38. Ogino S., Kubo S., Abdul-Karim F.W., Cohen M.L. Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatric and Developmental Pathology: The Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2001, 4:23-31.
39. Pandya K., Meeke K., Clementz A.G., Rogowski A., Roberts J., Miele L., Albain K.S., Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer 2011, 105:796-806.
40. Patereli A., Alexiou G.A., Stefanaki K., Moschovi M., Doussis-Anagnostopoulou I., Prodromou N., Karentzou O. Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors. Pediatric Neurosurgery 2010, 46:188-192.
41. Rabinovich B.A., Ye Y., Etto T., Chen J.Q., Levitsky H.I., Overwijk W.W., Cooper L.J., Gelovani J., Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14342-14346.
42. Radpour R., Barekati Z., Kohler C., Schumacher M.M., Grussenmeyer T., Jenoe P., Hartmann N., Moes S., Letzkus M., Bitzer J., Lefkovits I., Staedtler F., Zhong X.Y. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS One 2011, 6(11):e27355. Epub 2011 Nov 4.
43. Reddy A.T. Atypical teratoid/rhabdoid tumors of the central nervous system. Journal of Neuro-Oncology 2005, 75:309-313.
44. Rorke L.B., Packer R.J., Biegel J.A. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. Journal of Neurosurgery 1996, 85:56-65.
45. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., Gilmer T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Molecular Cancer Therapeutics 2001, 1:85-94.
46. Sanchez-Martin M., Pandiella A. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. International journal of cancer. Journal international du cancer 2011.
47. Seidel J., Kunc K., Possinger K., Jehn C., Luftner D. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochemical and Biophysical Research Communications 2011, 414:226-232.
48. Smith M.E., Das B.C., Kalpana G.V. In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines. Cancer Cellular International 2011, 11:34.
49. Tagliabue E., Agresti R., Carcangiu M.L., Ghirelli C., Morelli D., Campiglio M., Martel M., Giovanazzi R., Greco M., Balsari A., Menard S. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003, 362:527-533.
50. Taskar K.S., Rudraraju V., Mittapalli R.K., Samala R., Thorsheim H.R., Lockman J., Gril B., Hua E., Palmieri D., Polli J.W., Castellino S., Rubin S.D., Lockman P.R., Steeg P.S., Smith Q.R. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharmaceutical Research 2012, 29:770-781.
51. Zhang Z.K., Davies K.P., Allen J., Zhu L., Pestell R.G., Zagzag D., Kalpana G.V. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Molecular and Cellular Biology 2002, 22:5975-5988.